New daily pill aims to tame psoriatic arthritis symptoms
Disease control
Not yet recruiting
This phase 2 trial tests an experimental oral drug called CBP-0276 in adults with active psoriatic arthritis, a condition causing joint pain, swelling, and skin plaques. Participants receive either a low dose (200 mg), a high dose (800 mg), or a placebo daily for 24 weeks. The ma…
Phase: PHASE2 • Sponsor: Clarent Biopharma, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC